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Morphine

enhances Jipopo]ysaccharide-induced penneabiiity and IIlV-1 penetration of vascular endothelial
cell barriers.

Abstract

Using three types of in vitro endothelial cell barrier models, we investigated the

direct effects and mechanisms of morphine on vascular permeability.

Our current studies

illustrate LPS induces permeability across these VEC barriers, and is significantly

14

enhanced when co-treated with morphine, displayed using the [ CJ-inulin paracellular

marker.

Incubation with morphine alone induces permeability in a concentration

depeodent manner, and is not blocked by the addition of naloxone.

Morphine enhances

the detrimental effects of LPS on cell viability and alone also decreases endothelial cell

viability, concentration-dependently, which is also not affected by naloxone, as

demonstrated by the trypan blue exclusion assay. Using 4',6-diarnidino-2-phenylindole

(DAPI) nuclear stain, we reveal LPS- and morphine-induced cell death is through an

apoptotic mechanism.

Morphine-induced apoptosis is concentration-dependent and not

blocked by naloxone once again, and cotreatment with LPS synergizes to induce

enhanced apoptosis.

Morphine has been shown to induce Fas-mediated apoptosis in

immune cells (Yin et al., 1999); however, our VEC models demonstrate a Fas

independent apoptotic mechanism.

Lastly, we confirm that pretreatment of the

monolayer with morphine enhances viral penetration, using The Amplicor® Viral RNA

Detection Assay. These results suggest that morphine enhances permeability and viral

penetration across the vascular endothelium by promoting apoptosis, via a Fas

independent pathway.

This study reveals insight as to how morphine exposure may

enhance HIV -1 penetration and further implicate the effects of endotoxins on these

physiological barriers.

Introduction

The vessels of the vascular system arc lined by a continuous mono layer of endothelial

cells containing intercellular adherent and tight junctions.

These specialized junctions

function as a barrier against uncontrolled paracellular permeability (Kevil et al., 1998;

Rubin and Staddon, 1999; Li and Mrsny, 2000).

Thus, the vascular endothelial cell

(VEC) barrier provides a crucial interface between the circulating blood and the

underlying tissues (Hoek, 1992), and serves as a boundary to protect vital organ systems

from invasion by micropathogens such as the HIV-I virus (Baba et al., 1988; Zietz et al.,

1996; Notter, 1999).

Mechanical stress, intlanunation, or exogenous factors such as

drugs of abuse, including the opiate, morphine, may disrupt the VEC layer, leading to

edema and significant damage to the underlying tissues.

Previous studies have shown that chronic morphine exposure increases the

penetration of microorganisms across the epithelial lining of the GI tract (Hilberger et al.,

1997; Macfarlane et al., 2000; Bannerman and Golblum, 1997).

These studies suggest

that morphine may modulate the permeability of the GI tract epithelium, which contains

intercellular junctions similar to VEC.

However, the specific cellular and molecular

mechanisms underlying morphine's effects on the VEC barrier still need to be elucidated.

One mechanism by which morphine may alter VEC permeability is through the

promotion of programmed cell death or apoptosis.

Apoptosis, which is a normal cellular

process, may be induced prematurely by morphine's activation of certain intracellular

signals, such as the pro-apoptotic Fas-dependent pathway.

A recent study reported that

morphine induces the expression of the death receptor, Fas, in immune cells (Yin et al.,

1999).

The Fas-dependent pathway is initiated by the binding of the Fas-Ligand (FasL)

to the Fas receptor, thus, activating the Fas-Associated Death Domain (FADD) of the

receptor.

In turn, a cascade of caspases is triggered, mediating apoptotic cell death.

In

addition, a soluble form of the receptor, sFas, can exist in circulation, and has been

reported to block Fas-dependent apoptosis (Cheng et al., 1994).

Bacterial LPS is a complex glycolipid isolated from the cell walls of Gram-negative

bacteria.

LPS acts as a potent endotoxin, leading to an acute inflammatory response that

can ultimately result in endotoxic shock (Roy et al., 1999).

LPS has been shown to

induce production of an array of immune mediators, including the pro-apoptotic proteins,

FasL and sFas, in sinusoidal endothelial cells (Muschen et al., 1998).

Synergistic effects of morphine and LPS have been observed for various parameter,

of immune responses (Roy et al., 1999).

For example, chronic exposure to morphine has

been shown to enhance LPS induced production of pro-inflammatory cytokines that can

increase leukocyte adhesion to endothelial cells (Chang, 2001).

These cytokines have

been shown to enhance the permeability of the VEC barrier (Fiala et al., 1997).

In this study, we investigated whether morphine's actions on endothelial cells could

augment the effects of LPS and enhance the permeability of the VEC barrier, thus,

allowing viruses, such as lllV-1, to penetrate these physiological barriers.

We also

examined the mechanisms of in vitro endothelial cell death produced by LPS and

morphine, including the involvement of the Fas/FasL system.

Methods

Ch,mica/s and reagents.

Morphine sulfate-pentahydrate, naloxone-bydrochloride, LPS
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from Escherichia coli, [ C]-carboxylated inulin, Dulbecco's phosphate buffered saline

solution (DPBSS), and 4',6-diamidino-2-phenylindole (DAPI) nuclear stain were all

purchased from Sigma Chemical Co. (St. Louis, MO). Trypan blue solution (0.2%) was

purchased from GibcoLife Technologies, Inc (Rockville, MD). Recombinant human

Fas/FC Chimera (soluble Fas protein) was purchased from R & D Systems, Inc.

(Minneapolis, MN).

Fas-Ligand recombinant protein was purchased from Oncogene

Research Products (Cambridge, MA).

PRG-2 trypsin/EDTA solution for the rodent

endothelial cell line was purchased from Cell Systems, Inc. (Kirkland, WA).

Cell cultures.

Low passage (3"' or 4"') human coronary artery (hCAEC) and human brain

microvascular (hBMVEC) endothelial cells were purchased from Biowhittaker/Clonetics

(Walkersville, MD).

Cells were cultured in Clonetics EGM-2MV Bullet Kit media

supplemented with EGM-2 MY, and maintained at 37° C in a humidified 5% C02

incubator.

A Reagent Pack (Biowhittaker) containing Hepes buffered saline solution,

trypsin/EDTA solution, and trypsin neutralizing solution was also used for culturing the

human endothelial cell lines.

Immortalized rat brain microvascular endothelial cells

(rBMVEC), generously provided by Dr. D.B. Stanimirovic and Dr. A. Muruganandam

(National Research Council of Canada), were maintained as previously described

(Morley et al., 1998).

In vitro VEC barrier model.

An in vitro VEC barrier model was constructed as

described (Fiala et al., 1997) using hBMVEC, rBMVEC, and hCAEC cells, passage

numbers 5-8.

Briefly, the endothelial cells were seeded at a density of20,000

cells/0.3mL into a cell culture insert (8.0 µm pore size) housed in a 24-well tissne culture

plate (Fisher Scientific, Springfield, NJ), containing I mUwell

of culture medium.

For the LPS experiments, cells at 100% confluency, the medium in the top insert

chamber was replaced with either 0.3 mL of fresh medium (for controls), 0.3 mL of fresh

medium containing LPS (I, 10, or 100 µg/mL), or 0.3 mL of fresh medium containing 10

µM morphine plus 10 µg/mL LPS.

For the morphine experiments, the medium in the

upper chamber was replaced with morphine-supplemented medium (I, I 0, or I 00 µM).

The medium in all the lower chambers was replaced with 1.0 mL of fresh medium, and

the plates were incubated for 24 hat 37° C. Naloxone sensitivity was determined by pre

treating the cells in the top chamber with 0.3 mL of fresh medium containing 100 µM

naloxone for 20 min.

The naloxone-supplemented medium was then replaced with 0.3

mL of morphine (IO µM)-supplemented medium, and the plates were incubated for 24 h

at 37° C.

At the end of each treatment period, the medium in the upper chamber was replaced
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with 0.3 mL of fresh medium containing [ CJ-carboxylated inulin, and the medium in

the bottom chamber was replaced with I mL of fresh medium.

The cells were incubated

at 37' C for an additional 2 h to allow for diffusion. Fifty microliters of the medium from

each top and bottom chamber were then collected, mixed with liquid scintillation

cocktail, and counted in a liquid scintillation counter.

The permeability coefficient

14

(cm/min) for [

C]-inulin (MW 5000) was calculated using the formula previously

described by Fiala et al. (1997):

{VI (A* D)} * {pR/ pT },

where V = volume of the receptor chamber (1.0 cm'), A = area of the cell monolayer on

2),

the membrane (0.35 cm

D = initial amount of the marker molecule in the donor

chamber, pR/ pT = amount of the marker molecule in the receiver solution (pT = I hr. or

4hr.)

After each experiment, the upper chambers were stained with crystal violet and

observed with an Olympus Model IMT-2 inverted bright-phase compound microscope to

ensure minimal damage to the confluent monolayers.

Viability studies.

The primary endothelial cells were seeded at a density of 50,000

cells/well (passages 5-9) into 6-well plates containing 4 mUwell of fresh medium, and

Fresh medium (for controls), or medium containing

grown until -70% confluent.

morphine (I, IO, or 100 µM), naloxone (100 µM), morphine (IO µM) plus naloxone,

(IO µg/mL), or morphine (I O µM)

lus

p

LPS

incubated for an additional 24 hat 37° C.

(IO

mL) was

µg/

ded, and

ad

LPS

e cells were

th

Tue monolayers were examined with a phase

contrast microscope to ensure that they remained intact.

The supernatant was discarded,

and each well was washed twice with Hepes buffered saline solution

iowhittaker/Clonetics,

(B

th

alkersville, MD).

W

sin/EDTA, and the

wi

tryp

-2 (Passage Reagent

PRG

The human endothelial

sin was inactivated with

tryp

up)

Gro

in neutralizing solution.

tryps

sin/EDTA solution was used
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ce

to
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ent

rod

endothelial cell monolayers, which was then inactivated by addition of twice the amount

of cell culture medium.

The cells were centrifuged at 700 rpm at room temperature for

five minutes, and resuspended in fresh culture medium.

Cell viability was determined on

a hemacytometer by the trypan blue exclusion assay.

Nuclear staining assay. All three endothelial cell types (passages 6-9) were grown to

70% confluence on round glass coverslips (Fisher Scientific) in 24 well-plates.

One

milliliter of fresh medium containing the appropriate treatment was added in

quadruplicate, and the cells were incubated for an additional 24 hat 37° C.

The final

concentrations of the treatments were: 10 µM morphine ± 100 µM naloxone, 100 µM

naloxone, or 10 µg/mL LPS ± 10 µM morphine.

At the end of the 24 h incubation, the

cells were stained with 4',6-diamidino-2-phenylindole (DAPI), which intercalates DNA,

and, under UV light, the condensed, irregularly nuclei of apoptotic cells were

differentiated from the large, round nuclei of normal cells.

Briefly, DAPI staining was

performed by fixing the cells onto coverslips with 4% paraformaldehyde for 5-8 min,

rinsing the cells 3 times with PBS, then penneabilizing the cells with 95% ethanol/5%

acetic acid for 5-8 min.

The cells were then rinsed 3 times with PBS, and incubated in

the dark at room temperature with DAPI (final concentration - 300 nM in PBS) for 1-3

min.

After 3 PBS rinses, the coverslips were mounted with Pennount onto microscope

slides.

The cells were examined with an Olympus BX40 system microscope with an

Olympus BX-FLA reflected light fluorescence attachment at an excitation wavelength of

358 run and an emission wavelength of 461 run, and photographed with an Olympus

camera (Model number C-35AD-4) and 400 speed Kodak film with an exposure time of 1

minute.

Assessment o
f th• Fas/Fas-Ligand pathway.

The hBMVEC cell monolayers (passage 8-

10) were grown on round glass coverslips in 24-well plates, as described above, and

maintained at 37° C in a humidified environment.

When the cells reached 700/o

confluence, the medium was replaced with 900 µL of fresh medium and I 00 µL of

medium containing the appropriate treatment (4 wells/treatment).

The final

concentrations of the treatments were: 200 ng/mL FasL alone, 200 ng/mL FasL ± SO

ng/mL sFas, 10 µM morphine± SO ng/mL sFas, 10 µg/mL LPS ± SO ng/mL sFas, or SO

ng/mL sFas alone.

The cells were incubated for 24 hat 37° C, then analyzed for

apoptotic nuclei by fluorescent microscopy using the DAPI nuclear staining assay.

HIV-I penetration assays.

These experiments were performed by our collaborators, Ors.

Gujuluva and Fiala, of the department ofNeurology at UCLA School of Medicine, Los

Angeles, California.

Briefly, the VEC barrier model was constructed using the hCAEC
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cell line, as described previously in the in vitro VEC barrier models used for the [

inulin permeability assays (Fiala et al., 1997).

C]

When the cells reached 70% confluence,

the macrophage-tropic virus strain, HIV-1,R.fl. (150,000,000 RNA copies), was added to

the upper chamber with control vehicle, and incubated at 37' C for either 2 h or 24 h.

To

determine the effects of morphine on viral penetration across the VEC barrier, either

morphine (10 µMor 100 µM), or naloxone (100 µM) and morphine (10 µM) was added

to the upper chamber and incubated at 37° C for 24 h.

Approximately 150,000,000 RNA

copies of the HIV-I virus was then added to the upper chamber, and the plate was again

incubated at 37' C for 24 h.

After incubation, 50 µL samples were collected from both

the upper and lower chambers, and the number of HIV RNA copies was determined

according to Fiala et al. (1997) using the Amplicor® HIV -1 monitor test developed by

Roche Corp. Diagnostic Laboratories (Nutley, NJ).

The amount of virus in the morphine

treated samples was determined, and compared to the control vehicle standard.

This

experiment was repeated at least twice with reproducible results.

Statistical analysis.

For all studies, statistical significance of the results were determined

using ANOVA or the Student's I-test using the GraphPAD InStat software (GraphPad

Software, San Diego, CA).

Post-hoc statistics were computed using adjusted t-tests with

p-values corrected by the Bonferroni method.

standard 95% confidence interval (p<0.05).

Significance was evaluated using a

Individual samples were tested in triplicate

or quadruplicate for each experiment, and each experiment was repeated at least twice

with similar results.

Results

Morphine's effects on LPS-induced permeability o
f the VEC barrier.

The effects of the

bacterial endotoxin, LPS, on the hCAEC VEC barrier model were examined by

14

determining the penneability of the hCAEC monolayer to [ CJ-inulin.

Pre-treatrnent of

14

the hCAEC with I, 10, and 100 µg/mL LPS for 24 h significantly increased [

permeability in a concentration-dependent manner (Figure IA).

CJ-inulin

Co-treatrnent of the

14

model with IO µM morphine plus IO µg/mL LPS enhanced [

C]-inulin permeability

compared to LPS alone (Figure I B).

Morphine's effects on three different VEC barrier models were determined by pre

treating the hCAEC(A), hBMVEC (B), and rBMVEC (C) monolayers for 24 h with

either morphine alone (I, IO, or 100 µM), 100 µM naloxone alone, or 10 µM morphine

14

plus naloxone, then examining [

C]-inulin permeability (Figure 2).

either morphine or naloxone alone increased

[14C]-inulin

Treatment with

permeability (Figure 2), and co

treatment with morphine plus na1oxone resulted in an additive effect on

[14C]-inulin

permeability in all three of the endothelial cell lines tested (Figure 2).

Morphine's effects on cell viability o
f endothelial cells.

To determine if the change in

the VEC penneability produced by LPS and morphine occurred as a result of endothelial

cell death, the viability of the hCAEC (A), hBMVEC (B), and rBMVEC (C) cells was

examined.

Treatment with either morphine (JO µMand 100 µM) or naloxone (100 µM)

significantly decreased the viability of all three endothelial cell lines compared to control

(p<0.005, Figure 3).

Co-treatment with morphine (JO µM) plus naloxone lowered cell

viability in an additive manner compared to morphine alone (Figure 3).

LPS (IO µg/mL) treatment decreased the viability of the hCAEC, hBMVEC, and

rBMVEC cells (Figure 4A, B, and C, respectively) compared to untreated control

cultures.

All three endothelial cell types co-treated with morphine (IO µM) plus LPS had

a significantly lower percentage of viable cells compared to LPS treatment alone (Figure

4).

Apoplolic effects o
f morphine on endothelial cells.

Decreased cell viability can result

from either necrosis (physical or chemical damage to cells) or apoptosis (programmed

cell death). Necrosis due to physical damage was ruled out because microscopic

examination of the cell monolayers showed that the cells remained morphologically

intact following morphine treatment (data not shown).

Apoptosis can be identified by

characteristic morphological changes that occur in the nucleus of cells.

Using DAPI

nuclear staining, the nuclear morphology of the hBMVEC treated with IO µM morphine

with and without IO µg/mL LPS was examined.

The condensed, irregular nuclei of

apoptotic cells were then differentiated from the large, round nuclei of normal cells.

Untreated control hBMVEC cells contained morphologically normal nuclei (Figure SA);

whereas apoptotic nuclei were observed in the morphine- and LPS-treated cells (Figure

SB and C, respectively).

Co-treatment with morphine plus LPS resulted in both cells

with apoptotic nuclei and cells with normal nuclei (Figure SD).

The percentage of apoptotic cells was calculated for the hCAEC (A), hBMVEC (B),

and rBMVEC (C) following treatment with IO µM morphine, 100 µM naloxone,

morphine plus naloxone, IO µg/mL LPS, or morphine plus LPS.

Morphine treatment

induced apoptosis in all three endothelial cell types; this effect was not blocked by

naloxone (Figure 6).

In fact, the number of apoptotic cells was additive following

treatment with morphine plus naloxone compared to morphine treatment alone (Figure 6),

which is consistent with the decreased cell viability observed with morphine plus

naloxone treatment.

Treatment with LPS also resulted in apoptosis of the endothelial cells, which was

significantly enhanced by co-treatment with morphine (Figure 6).

Morphine's ejfecls on Fas-mediaJed endothelial cell apoptosis. Binding ofFasL to the

Fas receptor has been shown to promote apoptosis.

The soluble fonn of Fas, sFas, is

thought to inhibit the Fas/FasL apoptotic signaling pathway by blocking the binding of

FasL to the Fas receptor (Cheng et al., 1994).

We, therefore, investigated if the Fas

pathway could be involved in morphine's apoptotic effects on the VEC barrier.

hBMVEC cells treated with either 200 ng/mL FasL or 50 ng/mL sFas underwent

significant apoptosis when compared to untreated control monolayers (p<0.005, Figure

7A).

However, co-treatment of the monolayer with FasL plus sFas inhibited apoptosis

(Figure 7A).

Consistent with our previous results, treatment with 10 µM morphine alone

induced apoptosis (Figure 7A); whereas co-treatment with morphine plus sFas induced

apoptosis in an additive manner (Figure 1A).

Treatment with IO µg/mL LPS also induced significant apoptosis (Figure 7B).

However, this apoptotic effect was blocked by co-treatment with LPS plus sFas (Figure

7B).

Morphine's e
ff
ects

Oii

HlV-1 pe11etNtlo11 o
f 1111 ;,, 1'ilro VEC barrier.

Since exposure to

morphine resuhed in a significant increase in VEC petmeability, we then investigated if

morphine could alrect the penetration of viral particles, such as lilV-1, through the VEC

barrier.

Using the uhrasensitive Amplicor•viral RNA detection assay, we determined

the average number of viral RNA copies Iha! peoetratod into the lower chamber of the

bCAEC barrier model at 2 b and 24 h after addition ofIDV -1 to the upper chamber

(Figure 8).

A significant number of viral RNA copies penetrated into the lower chamber

at 24 h compared to the number at 2 h (p<0.005).

Treatment with morphine (IO µM or

100 µM) significantly increased the average number of!IlV-1 RNA copies penetrating

into the lower chamber in a dose-OepCDdc:ot manner (Fig= 8).
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Discussion

The vascular endothelial cell (VEC) barrier is important in providing an impermeable

interface between the cireulating blood and the underlying tissue.

Structurally, this

barrier is critical for protecting the host against pathogenic microorganisms such as the

HIV-I virus.

abuse.

However, the VEC can be compromised by infection and chronic opioid

In this study, we explored the mechanisms by which morphine enhances LPS

induced permeability of VEC barriers and promotes HIV- I penetration through those

barriers.

LPS is a bacterial endotoxin that affects the integrity of the vascular endothelial

lining (Bannerman and Goldblum, 1997).

Under pbase contrast light microscopy, there

are no obvious differences in the morphology of these cells; all three cell types,

rBMVEC, hBMVEC, and hCAEC grow into a confluent monolayer and present contact

inhibition of cell growth.

In our studies, both LPS and morphine decreased VEC viability

14

and increased the [

C]-inulin permeability in these three endothelial cell types tested.

Furthermore, morphine co-treatment significantly enhanced LPS-induced permeability of

the VEC, suggesting that the detrimental effects of LPS on the VEC barrier could be

significantly greater in the presence of morphine.

We then investigated the mechanism by which VEC viability and permeability could

be affected by morphine and LPS.

Cell death can occur as a result of either necrosis or

apoptosis (Farber, 1994; Tromp et al., 1997). Necrosis is characterized by cell membrane

swelling and bl ebbing, and the simultaneous death of large numbers of cells.

Apoptosis

is programmed cell death that results from intracellular signal transduction pathways, and

usually involves only a single or a few isolated cells at any given time. Nuclear staining

with DAPI and morphological examination confirmed that the decrease in cell viability

following treatment with either morphine or LPS alone, and in combination was due to

apoptosis, and not necrosis.

Such morphine-induced programmed cell death could

certainly contribute to enhanced VEC penneability and increase the possibility of

penetration by 1-IlV-l through the VEC barriers.

Preliminary studies showed that FasL, the natural ligand for Fas, induced apoptosis in

our VEC in a concentration-dependent manner, and that morphine pre-treatment

enhanced FasL-induced apoptosis, confirming the expression of a functional Fas receptor

in our cell types (data not shown).

Morphine has been shown to induce expression of Fas

in a T-cell hybridoma (Al.I), in mouse splenocytes, and freshly isolated human

peripheral blood lymphocytes (Yin et al., 1997).

Taken together, these results suggested

that morphine may prime the VEC to undergo FAS-mediated apoptosis.

The soluble

fonn of Fas, sFas, reportedly blocks Fas-dependent apoptosis (Cheng et al., 1994).

this study, we, therefore, used sFas to examine

dependent.

if

In

morphine's apoptotic effects were Fas

As expected, sFas did inhibit FasL-induced apoptosis.

Furthermore, when

the VEC monolayer was co-treated with LPS and sFas, apoptosis was inhibited,

suggesting that LPS-induced apoptosis is mediated via a Fas-dependent pathway.

Unexpectedly, sFas alone induced apoptosis of the endothelial cells, and co-treatment

with morphine

resulted in increased rather than decreased apoptotic effects.

These data

suggest that the molecular mechanisms underlying morphine-induced apoptosis

in

the

VEC monolayer are mediated through Fas-independent pathways although the VEC has

demonstrated functional Fas/Fas-L mediated apoptotic pathways.

Our studies are

consistent with previous studies showing variable data regarding the susceptibility of

vascular endothelial cells to Fas-mediated cell death and the expression of Fas-regulatory

components (Walsh and Sala, 1999).

Another possible mechanism by which morphine

may affect endothelial cell permeability is through the mu opioid receptor pathway.

The

presence of opioid receptors on endothelial cells has been shown by our laboratory (Vidal

et al., 1998) and others (Stefano et al., 1995; He et al., 2000).

While expression of mu

opioid receptor mRNA has been demonstrated in endothelial cells by both semi

quantitative and competitive RT-PCR (Vidal et al., 1998; Stefano et al., 1995), mu-opioid

binding sites have not been identified.

Furthermore, in our study, morphine's actions

were not reversed by naloxone, a mu opioid receptor antagonist.

Although we do not
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completely exclude the possibility that morphine's effects on [

CJ-inulin permeability,

cell viability, and apoptosis are mediated via opioid receptors, the data suggest that

morphine may act on these endothelial cells via a distinct, separate pathway, especially

considering a study by Melzig et al. (1998) showing binding of ['HJ-morphine within the

nuclei of endothelial cells.

These experiments demonstrate a mechanism of action for

morphine that is not mediated via opioid receptors, but rather binding to a separate

membrane or nuclear fraction of the endothelial cells.

Therefore, the underlying

mechanism of morphine, as reported here, still remains to be clarified.

The VEC barrier is one of the defense mechanisms through which vital organs are

protected from attack by pathogenic viruses such as HIV-I.

While HIV-I penetration

through our hCAEC barrier model was limited when exposure duration was short, the

penetration of HN-1 through the VEC barrier was significantly increased following

prolonged exposure to virus.

These results are consistent with a previous report, which

examined an in vitro blood-brain barrier model constructed from endothelial cells

isolated from microvascular vessels (1998).

In addition, pre-treatment of the hCAEC

barrier model with morphine enhanced HIV-I penetration. Taken together, these findings

suggest that the VEC barrier breaks down with prolonged exposure to HIV-I, and that the

integrity of the VEC barrier could be compromised further by the presence of morphine.

Consequently, in opioid addicts or in patients chronically treated with morphine for pain

relief, the VEC barrier may be compromised, allowing enhanced penetration of

pathogenic microorganisms, such as the HIV -1 virus.

HIV- I -associated encephalitis and cardiomyopathy are characterized by the

pronounced entry of the virus into the organ tissue environment (Fiala et al., 1997;

Persidsky et al., 1997).

The increased penetration of cell-free or cell-associated

pathogens that results from endothelial damage may contribute to the pathogenesis

associated with HIV- I infection (Berger et al., 1999).

In the presence of morphine, these

cell-free viruses may penetrate the physiological VEC barriers more effectively.

Our

results provide some insight into the mechanisms underlying how morphine exposure

may enhance HIV-I penetration through VEC barriers, and the detrimental effects that

endotoxins, such as LPS, may have on these physiological barriers.

Swnnuuy

The VEC berrier is one of the defense mechanisms by which vital organs are

protected from attack by pathogenic viruses such as HIV-I.

Our findings suggest that the

VEC barrier breaks down with prolonged exposure to HIV-I, and that the integrity of the

VEC bonier is compromised further in the presence of morphine.

Consequently, in

opioid addicts or in patients chronically treated with morphine for pain relict; the VEC

berrier may be breached, allowing this enhanced penetration of pathogenic

microorganisms, such as the HIV-I virus.

Our resuhs provide somo in.sight into the

mechanisms underlying how morphine exposure may enhsnce HIV-I penetration through

VEC barriers, and the detrimental effi:cts that endotoxins, such as LPS, may have on

these phY5iological berriers.
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